Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Four Stocks Hot on The Market on Wednesday?

SunOpta Inc. (NASDAQ:STKL) has risen by 7.77% in below-average trading, after posting results for its third quarter ended October 3. The company’s revenues mildly declined to $306 million during the most recent quarter, compared to $307.9 million from the prior-year period. Adjusted EBITDA was down to $16.8 million, compared to $18.8 million in the same period last year. Earnings from continuing operations jumped to $664,000, compared to a loss of $460,000 in the year-ago period. Meanwhile, earnings attributable to SunOpta Inc. (NASDAQ:STKL) were $314,000, compared to a loss of $384,000 reported a year earlier.

“We had an in-line quarter on an adjusted basis, and we believe performance will improve as we realize the benefits of the foundation we have built. Looking ahead, we are making good progress in our Consumer Products business, the integration of Sunrise Growers and reaping the benefits of the significant investments we have made in future growth,” SunOpta President and CEO Rik Jacobs said.

A total of 15 funds, out of 730 in our database, held 23.80% of the company’s outstanding stock at the end of June.

Follow Sunopta Inc. (NASDAQ:STKL)
Trade (NASDAQ:STKL) Now!

Glaukos Corp. (NYSE:GKOS), which identifies itself as an ophthalmic medical technology company, jumped 17.27% in active trading after slumping further in losses as it ended the third quarter of 2015.  The company’s net sales grew to $19 million in the third quarter this year, but Glaukos booked a net loss of $2.1 million – which widened slightly from the $2.0 net loss the same quarter in 2014. As an outlook, the company said it expects 2015 full-year net sales to be in the range of $70.5 million to $71.5 million.

“Glaukos has delivered another quarter of record performance that demonstrates the momentum building behind our first-in-class iStent technology as an elegant solution for managing intraocular pressure associated with glaucoma,” Glaukos President and CEO Thomas Burns said.

At the end of the second quarter, a total of nine funds among those we follow held 11.40% of the company’s outstanding stock.

Follow Glaukos Corp (NYSE:GKOS)
Trade (NYSE:GKOS) Now!

Disclosure: none.